Dog Immune-Mediated Polyarthritis Welfare and Management

Immune-mediated polyarthritis (IMPA) causes painful joint inflammation in multiple joints simultaneously, requiring immunosuppressive treatment and welfare-focused monitoring.

Key Facts

IMPA can be idiopathic or secondary to infection, drug reaction, or other immune stimulation
Affected dogs show shifting leg lameness, reluctance to move, fever, and joint swelling
Diagnosis requires joint fluid cytology showing sterile inflammatory cells in multiple joints
Corticosteroids are the primary treatment, with additional immunosuppressants for refractory cases
Idiopathic IMPA has a reasonable prognosis with treatment, but relapses are common and require retreatment

Welfare Considerations

IMPA causes diffuse joint pain that severely impairs mobility and quality of life. Affected dogs may be unable to rise, walk normally, or engage in any physical activity without pain. Fever compounds the systemic illness. Response to corticosteroids is typically rapid and dramatic, but side effects of high-dose immunosuppression including increased thirst, urination, appetite changes, and susceptibility to infection require monitoring. The risk of relapse during dose reduction is significant, and owners need to recognise early signs of recurrence. Long-term quality of life monitoring with regular owner assessment and veterinary examination guides treatment intensity.

What You Can Do

Seek urgent veterinary assessment for dogs showing acute onset lameness affecting multiple limbs with fever
Follow prescribed immunosuppressive therapy carefully and do not reduce doses without veterinary guidance
Monitor for signs of relapse during dose reduction including returning stiffness and reluctance to exercise
Investigate and address any underlying infectious trigger for secondary IMPA